У нас вы можете посмотреть бесплатно Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Joaquim Mullol from the Universitat de Barcelona, Spain, presents his research findings published in Allergy: Mullol, J, Laidlaw, TM, Bachert, C, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Allergy. 2021; 00: 1– 14. https://doi.org/10.1111/all.15067 Research highlights: • In patients pooled from the SINUS-24 (NCT02912468) and SINUS-52 (NCT02898454) studies, patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD) represent a severe and difficult-to-treat population • Improvements in disease control, lung function, and symptom burden were observed with dupilumab treatment versus placebo, irrespective of NSAID-ERD status • The dupilumab treatment effect was greater in NSAID-ERD patients for nasal congestion, SNOT-22 total score, total symptom score, and peak nasal inspiratory flow. Follow Allergy on: Facebook: / eaaciallergy Twitter: / allergyeaaci LinkedIn: / allergy-eaaci Instagram: / allergy.eaaci Like, share and comment on our videos, thank you. https://journalallergy.com/